Phase IIINeuropeptide
Compound 61694
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061694
Risk Class
MODERATE
Last Audit
Jun 16, 2108
Research Abstract
Neuropeptide candidate engineered for cellular repair initiatives with automated dossier coverage.
Compound 61694 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for cellular repair and tissue regeneration.
The dossier currently sits in phase iii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061694 with updates logged 2108-06-16.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Cellular repairTissue regeneration
Nomenclature
CX-61694Neuropeptide Program 61694
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061694
- [2] Operations Pulse • Neuropeptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61694